Showing results (261-270 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|April 18, 2025
Identification of SURF4 and RALGAPA1 as promising therapeutic targets in glioblastoma and pan-cancer through integrative multi-omics, CRISPR-Cas9 screening and prognostic meta-analysisFei Wang, Yuxuan Chen, Run Huang, et al.Cancer Immunology, Immunotherapy : CII|April 19, 2025
Identification and validation of poor prognosis immunoevasive subtype of esophageal cancer with tumor-infiltrating SAMD3 + NK cell abundanceXu Huang, Runze You, Fangyi Liu, et al.Cancer Immunology, Immunotherapy : CII|May 22, 2025
Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLCQianqian Zhang, Guoxin Wang, Wenjie Yan, et al.Cancer Immunology, Immunotherapy : CII|May 15, 2025
Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescencePujan Engels, Andras Szolek, Sebastian Hörner, et al.Cancer Immunology, Immunotherapy : CII|May 14, 2025
Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expressionMona Alhussein Aboalela, Mohamed Abdelmoneim, Shigeru Matsumura, et al.Cancer Immunology, Immunotherapy : CII|May 16, 2025
Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinomaChien-Huai Chuang, Ching-Tso Chen, Chih-Hung Hsu, et al.Cancer Immunology, Immunotherapy : CII|June 17, 2025
Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective studyMingfen Lai, Shuai Li, Zhongwen Jin, et al.Cancer Immunology, Immunotherapy : CII|May 10, 2025
Knockdown NEK7 stimulates anti-tumor immune responses by NLRP3/PD-L1 signaling in esophageal cancerLi Wang, Yurong Cheng, Weiqiang Li, et al.Cancer Immunology, Immunotherapy : CII|January 31, 2026
Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German populationMoritz Weber, Alexander Freiherr von Hammerstein-Equord, Manuela Weinreich, et al.Cancer Immunology, Immunotherapy : CII|January 27, 2026
Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trialsWei-Wu Chen, Shi-Cheng Li, Qian Yin, et al.Pageof 650